The effects of various combinations of different classes of anticancer drugs and tyrosine kinase inhibitors on the human MCF-7 and triple-negative MDA-MB 231 breast carcinoma cell lines
type: CreativeWork
description: Globally, breast cancer is the most common cancer affecting women and it is predicted that in 2030 about 12 million deaths will occur with approximately 21.7 million new cases. Genetic risk factors as well as race and ethnicity, account for about 5-10% of all breast cancer occurrences. Triple negative breast cancer (TNBC), tumors that tested negative for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), contribute to 10-20% of all breast carcinomas and is known to be a more aggressive type of cancer with varying degree of response to chemotherapeutic and radiation therapy. The epidermal growth factor receptor (EGFR) is abnormally activated in many cancers and its signal transduction pathways play an important role in regulating cell proliferation and survival. It is often overexpressed in TNBC. P-glycoprotein (P-gp) is a transmembrane glycoprotein responsible for active transport of substances across the cell membrane out of a cell. It functions as an efflux pump and is overexpressed in many cancer cells. The altered expression of both EGFR and P-gp parallels an aggressive clinical course and the development of resistance to anticancer and adjuvant endocrine therapies. Anti-EGFR compounds that specifically target the intracellular and extracellular domains of the EGFR include tyrosine kinase inhibitors (TKIs), e.g., gefitinib and erlotinib and monoclonal antibodies, e.g., cetuximab and trastuzamab, that are amongst the most effective agents that are currently used together with chemotherapeutic agents in clinical practice. However, the emergence of multidrug resistance (MDR), a mechanism that is not well understood, has, over time, eclipsed the progress that has been made in drug therapeutics. In this study we examined the effects of doxorubicin (DOX), cisplatin (CDDP) and one investigational TKI (EGFR inhibitor I, hereinafter referred to as EGFRi), individually and in combination, on human MCF-7 breast carcinom…
abstract: Globally, breast cancer is the most common cancer affecting women and it is predicted that in 2030 about 12 million deaths will occur with approximately 21.7 million new cases. Genetic risk factors as well as race and ethnicity, account for about 5-10% of all breast cancer occurrences. Triple negative breast cancer (TNBC), tumors that tested negative for oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), contribute to 10-20% of all breast carcinomas and is known to be a more aggressive type of cancer with varying degree of response to chemotherapeutic and radiation therapy. The epidermal growth factor receptor (EGFR) is abnormally activated in many cancers and its signal transduction pathways play an important role in regulating cell proliferation and survival. It is often overexpressed in TNBC. P-glycoprotein (P-gp) is a transmembrane glycoprotein responsible for active transport of substances across the cell membrane out of a cell. It functions as an efflux pump and is overexpressed in many cancer cells. The altered expression of both EGFR and P-gp parallels an aggressive clinical course and the development of resistance to anticancer and adjuvant endocrine therapies. Anti-EGFR compounds that specifically target the intracellular and extracellular domains of the EGFR include tyrosine kinase inhibitors (TKIs), e.g., gefitinib and erlotinib and monoclonal antibodies, e.g., cetuximab and trastuzamab, that are amongst the most effective agents that are currently used together with chemotherapeutic agents in clinical practice. However, the emergence of multidrug resistance (MDR), a mechanism that is not well understood, has, over time, eclipsed the progress that has been made in drug therapeutics. In this study we examined the effects of doxorubicin (DOX), cisplatin (CDDP) and one investigational TKI (EGFR inhibitor I, hereinafter referred to as EGFRi), individually and in combination, on human MCF-7 breast carcinom…
author: Abrahams, Beynon
keywords: Breast cancer, MCF-7 breast carcinoma cells, MDA-MB-231 TNBC cells, Tyrosine kinase inhibitor, EGFR inhibitor
license: https://uwcscholar.uwc.ac.za/bitstreams/1caf5d4f-e76d-47c6-b3a7-850e2682bd62/download
date published: 2020
date modified: 2026-07-24T06:00:56Z
provider: University of the Western Cape
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: University of the Western Cape